『Open-Label Phase II Study of the Efficacy of Nivolumab for Cancer of Unknown Primary』（Ann Oncol 2021, Accepted 21 Nov. 2021）より まとめ 既治療の原発不明がんに対しニボルマブは奏効率22.2% 要約 〇原発不明がん（cancer of unknown primary :…

『Thoracic surgery improved overall survival in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment』（Lung Cancer 2021;162:29） まとめ E…